Rosanna Cardani

List of Publications by Citations

67 papers	1,562 citations	21 h-index	37 g-index
67 ext. papers	1,853 ext. citations	3.6 avg, IF	4.72 L-index

#	Paper	IF	Citations
67	Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. *FASEB Journal*, **2009**, 23, 3335-46	0.9	207
66	Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2015**, 1852, 594-606	6.9	201
65	Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. *Neuromuscular Disorders*, **2011**, 21, 81-8	2.9	90
64	Deregulated microRNAs in myotonic dystrophy type 2. *PLoS ONE*, **2012**, 7, e39732	3.7	71
63	Myotonic dystrophy type 2 and related myotonic disorders. *Journal of Neurology*, **2004**, 251, 1173-82	5.5	64
62	Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. *Acta Neuropathologica*, **2010**, 119, 465-79	14.3	51
61	Plasma microRNAs as biomarkers for myotonic dystrophy type 1. *Neuromuscular Disorders*, **2014**, 24, 509-15	2.9	50
60	Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. *European Journal of Histochemistry*, **2004**, 48, 437-42	2.1	49
59	CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients. *Molecular Therapy - Nucleic Acids*, **2017**, 9, 337-348	10.7	44
58	Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome. *Journal of Clinical Medicine*, **2020**, 9,	5.1	36
57	Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1. *Scientific Reports*, **2016**, 6, 38174	4.9	36
56	Activation of the Pro-Oxidant PKC□-p66Shc Signaling Pathway Contributes to Pericyte Dysfunction in Skeletal Muscles of Patients With Diabetes With Critical Limb Ischemia. *Diabetes*, **2016**, 65, 3691-3704	0.9	35
55	Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism. *Journal of Neuromuscular Diseases*, **2015**, 2, S59-S71	5	34
54	Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. *Journal of Neurology*, **2012**, 259, 2090-9	5.5	34
53	Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects. *Neurological Sciences*, **2017**, 38, 535-546	3.5	31
52	SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype. *Neuromuscular Disorders*, **2015**, 25, 301-7	2.9	28
51	Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle. *PLoS ONE*, **2017**, 12, e0184987	3.7	27

50	Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic dystrophy type 2. *PLoS ONE*, **2013**, 8, e83777	3.7	27
49	Muscle biopsy. *Journal of Neurology*, **2012**, 259, 601-10	5.5	25
48	Workshop Report: consensus on biomarkers of cerebral involvement in myotonic dystrophy, 2-3 December 2014, Milan, Italy. *Neuromuscular Disorders*, **2015**, 25, 813-23	2.9	21
47	Premature senescence in primary muscle cultures of myotonic dystrophy type 2 is not associated with p16 induction. *European Journal of Histochemistry*, **2014**, 58, 2444	2.1	21
46	Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2. *Neuromuscular Disorders*, **2009**, 19, 335-43	2.9	21
45	Genome wide identification of aberrant alternative splicing events in myotonic dystrophy type 2. *PLoS ONE*, **2014**, 9, e93983	3.7	19
44	Cultured myoblasts from patients affected by myotonic dystrophy type 2 exhibit senescence-related features: ultrastructural evidence. *European Journal of Histochemistry*, **2011**, 55, e26	2.1	19
43	Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	18
42	RNA processing is altered in skeletal muscle nuclei of patients affected by myotonic dystrophy. *Histochemistry and Cell Biology*, **2011**, 135, 419-25	2.4	17
41	A putative role of ribonuclear inclusions and MBNL1 in the impairment of gallbladder smooth muscle contractility with cholelithiasis in myotonic dystrophy type 1. *Neuromuscular Disorders*, **2008**, 18, 641-5	2.9	17
40	Aberrant insulin receptor expression is associated with insulin resistance and skeletal muscle atrophy in myotonic dystrophies. *PLoS ONE*, **2019**, 14, e0214254	3.7	14
39	Nuclear ribonucleoprotein-containing foci increase in size in non-dividing cells from patients with myotonic dystrophy type 2. *Histochemistry and Cell Biology*, **2012**, 138, 699-707	2.4	14
38	Muscleblind-like1 undergoes ectopic relocation in the nuclei of skeletal muscles in myotonic dystrophy and sarcopenia. *European Journal of Histochemistry*, **2013**, 57, e15	2.1	14
37	RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study. *European Journal of Histochemistry*, **2009**, 53, e18	2.1	14
36	Proteome profile in Myotonic Dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways. *Neurobiology of Disease*, **2010**, 38, 273-80	7.5	14
35	Progression of muscle histopathology but not of spliceopathy in myotonic dystrophy type 2. *Neuromuscular Disorders*, **2014**, 24, 1042-53	2.9	12
34	Age-related cell proliferation and apoptosis in the kidney of male Fischer 344 rats with observations on a spontaneous tubular cell adenoma. *Toxicologic Pathology*, **2000**, 28, 802-6	2.1	12
33	High-sensitive cardiac troponin T (hs-cTnT) assay as serum biomarker to predict cardiac risk in myotonic dystrophy: A case-control study. *Clinica Chimica Acta*, **2016**, 463, 122-128	6.2	11

32	High-throughput analysis of the RNA-induced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2. *Cell Death and Disease*, **2018**, 9, 729	9.8	11
31	Flecainide-Induced Brugada Syndrome in a Patient With Skeletal Muscle Sodium Channelopathy: A Case Report With Critical Therapeutical Implications and Review of the Literature. *Frontiers in Neurology*, **2018**, 9, 385	4.1	11
30	Immunohistochemical localization of beta 1-adrenergic receptors in the liver of male and female F344 rat. *Histochemistry and Cell Biology*, **2001**, 116, 441-5	2.4	11
29	Routinely frozen biopsies of human skeletal muscle are suitable for morphological and immunocytochemical analyses at transmission electron microscopy. *European Journal of Histochemistry*, **2010**, 54, e31	2.1	10
28	Soluble Receptor for Advanced Glycation End Products and Its Forms in COVID-19 Patients with and without Diabetes Mellitus: A Pilot Study on Their Role as Disease Biomarkers. *Journal of Clinical Medicine*, **2020**, 9,	5.1	10
27	RNA Transcription and Maturation in Skeletal Muscle Cells are Similarly Impaired in Myotonic Dystrophy and Sarcopenia: The Ultrastructural Evidence. *Frontiers in Aging Neuroscience*, **2014**, 6, 196	5.3	9
26	The analysis of myotonia congenita mutations discloses functional clusters of amino acids within the CBS2 domain and the C-terminal peptide of the ClC-1 channel. *Human Mutation*, **2018**, 39, 1273-1283	4.7	9
25	Development and Validation of a New Molecular Diagnostic Assay for Detection of Myotonic Dystrophy Type 2. *Genetic Testing and Molecular Biomarkers*, **2015**, 19, 703-9	1.6	8
24	SCN4A as modifier gene in patients with myotonic dystrophy type 2. *Scientific Reports*, **2018**, 8, 11058	4.9	8
23	Ribonuclear inclusions as biomarker of myotonic dystrophy type 2, even in improperly frozen or defrozen skeletal muscle biopsies. *European Journal of Histochemistry*, **2009**, 53, e13	2.1	8
22	Neuropsychological and Psychological Functioning Aspects in Myotonic Dystrophy Type 1 Patients in Italy. *Frontiers in Neurology*, **2018**, 9, 751	4.1	7
21	Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach. *Journal of Neurology*, **2017**, 264, 1705-1714	5.5	6
20	Aberrant regulation of epigenetic modifiers contributes to the pathogenesis in patients with selenoprotein N-related myopathies. *Human Mutation*, **2019**, 40, 962-974	4.7	6
19	Cardiac involvement in myotonic dystrophy: The role of troponins and N-terminal pro B-type natriuretic peptide. *Atherosclerosis*, **2017**, 267, 110-115	3.1	6
18	Human myoblasts from skeletal muscle biopsies: in vitro culture preparations for morphological and cytochemical analyses at light and electron microscopy. *Methods in Molecular Biology*, **2013**, 976, 67-79	1.4	6
17	Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2. *Frontiers in Neurology*, **2019**, 10, 992	4.1	5
16	Circulating Irisin Is Reduced in Male Patients with Type 1 and Type 2 Myotonic Dystrophies. *Frontiers in Endocrinology*, **2017**, 8, 320	5.7	5
15	Proximal myotonic dystrophy mimicking progressive muscular atrophy. *European Journal of Neurology*, **2005**, 12, 160-1	6	5

14	Tibialis anterior muscle needle biopsy and sensitive biomolecular methods: a useful tool in myotonic dystrophy type 1. *European Journal of Histochemistry*, **2015**, 59, 2562	2.1	4
13	Effect of glucose stress conditions in BL6T murine melanoma cells. *Melanoma Research*, **2004**, 14, 345-51	3.3	3
12	Characterization of sarcoplasmic reticulum Ca(2+) ATPase pumps in muscle of patients with myotonic dystrophy and with hypothyroid myopathy. *Neuromuscular Disorders*, **2016**, 26, 378-85	2.9	3
11	Rare Disease: Cardiac Risk Assessment With MRI in Patients With Myotonic Dystrophy Type 1. *Frontiers in Neurology*, **2020**, 11, 192	4.1	3
10	Influence of beta-adrenergic antagonists on cell proliferation rates in the kidney of untreated and diethylnitrosamine-treated male F344 rats. *Chemico-Biological Interactions*, **1999**, 118, 217-31	5	2
9	Decreased density of beta1-adrenergic receptors in preneoplastic and neoplastic liver lesions of F344 rats. *Histology and Histopathology*, **2005**, 20, 843-50	1.4	2
8	Clinical Reasoning: A 35-year-old woman with hyperstartling, stiffness, and accidental falls: A startling diagnosis. *Neurology*, **2017**, 88, e38-e41	6.5	1
7	Myotonic dystrophy type 2 and autoimmune chronic gastritis: an incidental association?. *Neurological Sciences*, **2011**, 32, 1249-50	3.5	1
6	A 14-Year Italian Experience in DM2 Genetic Testing: Frequency and Distribution of Normal and Premutated Alleles. *Frontiers in Genetics*, **2021**, 12, 668094	4.5	1
5	Drug resistant focal epilepsy in a patient with myotonic dystrophy type 2: casual or causal association?. *Neurological Sciences*, **2016**, 37, 1867-1868	3.5	1
4	Incidence of amplification failure in DMPK allele due to allelic dropout event in a diagnostic laboratory. *Clinica Chimica Acta*, **2018**, 484, 111-116	6.2	1
3	Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention		1
2	CLINICAL ASPECTS AND MANAGEMENT OF MYOTONIC DYSTROPHIES. *Istituto Lombardo - Accademia Di Scienze E Lettere - Incontri Di Studio*, **2014**, 41-65	0	
1	Myotonic dystrophies **2016**, 472-475		